Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

Molecular diagnosis & therapy - 1 Dec 2010

Shiroiwa Takeru, Motoo Yoshiharu, Tsutani Kiichiro

Abstract excerpt

BACKGROUND: Cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor, improves progression-free survival and overall survival in patients with metastatic colorectal cancer (mCRC). However, patients with a KRAS gene mutation do not benefit from cetuximab therapy. METHODS: We performed a cost-effectiveness analysis of KRAS testing and cetuximab treatment as last-line therapy for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Cost-Benefit Analysis

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Survival Analysis

Source

Identifiers

PMID: 21275455
DOI: 10.1007/BF03256395

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.PMID 21275455Read ↗

Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.Semantic proximity Read ↗

Cost-Effectiveness of RAS Genetic Testing Strategies in Patients With Metastatic Colorectal Cancer: A Systematic Review.Semantic proximity Read ↗

KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.Semantic proximity Read ↗

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.Semantic proximity Read ↗

Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.Semantic proximity Read ↗

KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.Semantic proximity Read ↗

Real-world cost-effectiveness of panel-based genomic testing to inform therapeutic decisions for metastatic colorectal cancer.Semantic proximity Read ↗

Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.Semantic proximity Read ↗

A Cost-effectiveness Analysis of Adding Cetuximab to the First-line Treatment of Metastatic Colorectal Carcinoma in Iran; Considering Genetic Screening for Precision MedicineSemantic proximity Read ↗

Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.Semantic proximity Read ↗

Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.Semantic proximity Read ↗

Economic Evaluation of Companion Diagnostic Testing for EGFR Mutations and First-Line Targeted Therapy in Advanced Non-Small Cell Lung Cancer Patients in South Korea.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.